Clinical evidences of low-dose rivaroxaban + acetylsalicylic acid treatment – who should be treated with dual pathway antithrombotic therapy?

Abstract

Atherosclerotic cardiovascular diseases cause the highest number of deaths worldwide. To reduce cardiovascular mortality, the use of appropriate antithrombotic treatment in secondary prevention is crucial. A special form of antithrombotic therapy is combined low-dose rivaroxaban + acetylsalicylic acid treatment (dual inhibition), for which there is clinical evidence in a wide range of high-risk atherosclerotic patients (after acute coronary syndrome, chronic coronary syndrome, peripheral arterial patients and after peripheral vascular intervention). The aim of this paper is to summarize clinical experience with this therapeutic strategy and to make recommendation for daily practice for low-dose rivaroxaban + acetylsalicylic acid treatment.

Keywords

• atherosclerosis
• cardiovascular diseases
• peripheral arterial disease
• antithrombotic therapy
• rivaroxaban
• acetylsalicylic acid